CA Patent

CA2940902C — Polymorphs and solid states of tiacumicin b

Assigned to Xellia Pharmaceuticals ApS · Expires 2022-10-25 · 4y expired

What this patent protects

The present invention relates to new polymorphs consiting in crystallines solvates of Tiacumicin B, the solvates being propanol, isopropanol, acetic acid, isopropyl acetate, chlorobenzene and methyl-ethyl-ketone. The present invention also relates to a new amorphous form of Tiacu…

USPTO Abstract

The present invention relates to new polymorphs consiting in crystallines solvates of Tiacumicin B, the solvates being propanol, isopropanol, acetic acid, isopropyl acetate, chlorobenzene and methyl-ethyl-ketone. The present invention also relates to a new amorphous form of Tiacumicin B.

Drugs covered by this patent

Patent Metadata

Patent number
CA2940902C
Jurisdiction
CA
Classification
—
Expires
2022-10-25
Drug substance claim
No
Drug product claim
No
Assignee
Xellia Pharmaceuticals ApS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.